Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Etanercept in Patients With Plaque Psoriasis After Stopping Ciclosporin Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between age 18 and 70 years~* Active and stable plaque psoriasis with a BSA≥10 or PASI≥10.~Exclusion Criteria:~* Evidence of skin conditions other than psoriasis~* Psoralen plus psoralen + ultraviolet A (PUVA), ciclosporin, acitretin, alefacept, anakinra, or any other systemic anti-psoriasis therapy or disease-modifying antirheumatic drugs (DMARD) with 28 days of screening~* ultraviolet B (UVB) therapy, topical steroids, topical Vitamin A or D analog preparations, or anthralin~* Prior exposure to any TNF-inhibitor. Prior exposure to efalizumab~* Corticosteroid dose of prednisone \>10 mg/day~* Serious infection~* Receipt of any live vaccine~* Abnormal hematology or chemistry~* Body mass index (BMI) \> 38~* Pregnancy or Breastfeeding~* Significant concurrent medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- etanercept (Type: EXPERIMENTAL): Participants were administered a 50 mg dose of etanercept subcutaneously once a week after an initial course of ciclosporin.
- placebo (Type: PLACEBO_COMPARATOR): Participants were administered placebo subcutaneously once a week after an initial course of ciclosporin.

Based on this trial design, predict the completion outcome and termination type (if applicable).